肝硬化和肝移植患者第二剂疫苗接种后的免疫应答
这项前瞻性队列研究比较了194例患者(141例肝移植、53例肝硬化)和56名健康对照在第二剂SARS-CoV-2疫苗接种后的体液和T细胞免疫应答。肝移植受者抗体阳转率为63%,显著低于肝硬化患者的100%,且T细胞应答率仅36.6%,28%的肝移植受者无任何应答。建议对低应答者进行常规血清学检测并接种第三剂疫苗。
要点
- 肝移植受者第二剂疫苗接种后抗体阳转率仅63%,T细胞应答率36.6%。
- 28%的肝移植受者既无体液也无T细胞应答,属高风险人群。
- 年龄>65岁和高血压是肝移植受者低应答的预测因素。
核心结论
- 肝移植受者第二剂疫苗接种后体液和T细胞应答均显著低于肝硬化和健康对照。
- 建议对低应答或不应答者进行常规血清学检测并接种第三剂疫苗。
研究设计与样本
- 前瞻性队列研究,纳入194例患者(141例肝移植、53例肝硬化Child-Pugh A-C)和56名健康对照。
- 在第二剂疫苗接种前及接种后10至84天检测抗SARS-CoV-2刺突蛋白滴度和T细胞应答。
主要发现
- 抗S三聚体检测显示肝移植受者抗体阳转率为63%,肝硬化患者和对照均为100%。
- 肝移植受者中应答者的抗SARS-CoV-2中位滴度低于肝硬化患者和对照(P < .001)。
- 刺突特异性T细胞应答率在肝移植、肝硬化和对照中分别为36.6%、65.4%和100%。
- 28%的肝移植受者第二剂疫苗接种后既无体液也无T细胞应答。
关键数值与推荐
- 肝移植受者无应答或低体液应答的预测因素:年龄>65岁(OR 4.57, 95%CI 1.48-14.05)和高血压(OR 2.50, 95%CI 1.10-5.68)。
- 钙调神经磷酸酶抑制剂单药治疗相比其他免疫抑制方案,疫苗接种失败可能性更低(OR 0.36, 95%CI 0.13-0.99)。
临床怎么用
- 对肝移植受者第二剂疫苗接种后进行常规血清学检测以评估应答。
- 对低应答或不应答患者考虑接种第三剂疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Detailed information on the immune response after second vaccination of cirrhotic patients and liver transplant (LT) recipients against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is largely missing. We aimed at comparing the vaccine-induced humoral and T-cell responses of these vulnerable patient groups. METHODS: In this prospective cohort study, anti-SARS-CoV-2 spike-protein titers were determined using the DiaSorin LIAISON (anti-S trimer) and Roche Elecsys (anti-S RBD) immunoassays in 194 patients (141 LT, 53 cirrhosis Child-Pugh A-C) and 56 healthy controls before and 10 to 84 days after second vaccination. The spike-specific T-cell response was assessed using an interferon-gamma release assay (EUROIMMUN). A logistic regression analysis was performed to identify predictors of low response. RESULTS: After the second vaccination, seroconversion was achieved in 63% of LT recipients and 100% of cirrhotic patients and controls using the anti-S trimer assay. Median anti-SARS-CoV-2 titers of responding LT recipients were lower compared with cirrhotic patients and controls (P < .001). Spike-specific T-cell response rates were 36.6%, 65.4%, and 100% in LT, cirrhosis, and controls, respectively. Altogether, 28% of LT recipients did neither develop a humoral nor a T-cell response after second vaccination. In LT recipients, significant predictors of absent or low humoral response were age >65 years (odds ratio [OR], 4.57; 95% confidence interval [CI], 1.48-14.05) and arterial hypertension (OR, 2.50; 95% CI, 1.10-5.68), whereas vaccination failure was less likely with calcineurin inhibitor monotherapy than with other immunosuppressive regimens (OR, 0.36; 95% CI, 0.13-0.99). CONCLUSION: Routine serological testing of the vaccination response and a third vaccination in patients with low or absent response seem advisable. These vulnerable cohorts need further research on the effects of heterologous vaccination and intermittent reduction of immunosuppression before booster vaccinations.
引用
- Ruether DF, Schaub GM, Duengelhoef PM, et al. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Clin Gastroenterol Hepatol. 2021. PMID: 34509643. doi:10.1016/j.cgh.2021.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。